文献速递免疫规划

食蟹猴免疫接种hVEGF26-104/RFASE的安全性和免疫原性研究

A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys.
PubMed 文献 · Vaccine · 2018-03-05

在54只食蟹猴中分7组接种靶向hVEGF165的治疗性疫苗hVEGF26-104/RFASE,每2周免疫一次共4次,监测至末次免疫后3天。结果显示免疫诱导RFASE佐剂依赖性急性期反应,产生高滴度抗hVEGF26-104且与hVEGF165交叉反应的抗体,可抑制贝伐珠单抗与hVEGF165结合及hVEGF165生物活性,未观察到VEGF中和常见的不良事件。

要点

  • 食蟹猴4次免疫后产生高滴度抗hVEGF26-104抗体并与hVEGF165交叉反应。
  • 免疫血清可抑制贝伐珠单抗与hVEGF165结合及hVEGF165生物活性。
  • 研究期间未观察到VEGF中和常见的不良事件。

核心结论

  • hVEGF26-104/RFASE可安全用于食蟹猴,诱导所需免疫应答,支持该疫苗的临床开发。

研究设计与样本

  • 共使用54只食蟹猴,分为7组;第1-3组为对照组,分别单用PBS(第1组)、单用RFASE(第2组)或单用hVEGF26-104(第3组);第4-7组接受hVEGF26-104联合RFASE,抗原或佐剂剂量不同。
  • 所有动物均免疫4次,间隔2周,安全性和免疫原性监测至末次免疫后3天。

主要发现

  • 免疫诱导RFASE佐剂依赖性急性期反应。
  • 初次免疫后28天,猴血清中检出高滴度抗hVEGF26-104抗体,且与hVEGF165交叉反应。
  • 这些抗体在竞争ELISA中能抑制单克隆抗体贝伐珠单抗与hVEGF165的结合。
  • 在VEGF特异性生物测定中,加入免疫猴血清可抑制hVEGF165的生物活性。
  • 整个研究期间未观察到VEGF中和常见的不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vascular endothelial growth factor (VEGF) is pivotal in tumor angiogenesis and therapies targeting the VEGF axis are widely used in the clinic for the treatment of cancer. We have developed a therapeutic vaccine targeting human (h)VEGF165. hVEGF26-104/RFASE is based on the truncated protein hVEGF26-104 as antigen formulated in an oil-in-water emulsion containing the sulpholipopolysaccharide RFASE as adjuvant. Here we describe the toxicity and immunogenicity of this therapeutic vaccine in cynomolgus monkeys. METHODS: In total 54 cynomolgus monkeys were used and divided in 7 groups. Groups 1-3 were control groups, either receiving PBS alone (group 1), RFASE alone (group 2) or hVEGF26-104 alone (group 3). Animals allocated to groups 4-7 received hVEGF26-104 together with RFASE, but with varying doses of the antigen or the adjuvant. All animals were immunized four times with 2-week intervals and safety and immunogenicity were monitored until 3 days after the final immunization. RESULTS: Immunization induced an RFASE adjuvant dependent acute phase response. High titers of antibodies against hVEGF26-104 and cross-reactive with hVEGF165, were found in monkey sera, 28 days after primer immunization. These antibodies were able to inhibit the binding of the monoclonal antibody bevacizumab with hVEGF165 in a competition ELISA. Moreover, the biological activity of hVEGF165 could be inhibited by the addition of immunized monkey serum in a VEGF specific bioassay. Importantly, no adverse events commonly observed with VEGF neutralization were observed throughout the study. CONCLUSION: These data show that hVEGF26-104/RFASE can be safely administered in cynomolgus monkeys, induces the desired immune response and therefore support the clinical development of this vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wentink MQ, Verheul HMW, Griffioen AW, et al. A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys. Vaccine. 2018. PMID: 29519591. doi:10.1016/j.vaccine.2018.02.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。